AC Immune Reports Positive Phase 1 ALS Imaging Data for ACI-19626
LAUSANNE, Switzerland, May 22, 2026 AC Immune announced new preliminary Phase 1 data showing that its investigational TDP-43 PET...
PET imaging
Advertisement
Bayer PET Tracer Shows Promise in Amyloidosis Study
BERLIN, Germany / WHIPPANY, N.J., May 7, 2026 Bayer announced positive topline results from the pivotal Phase III REVEAL...
Telix NDA Accepted for Pixclara Brain Cancer Imaging
Melbourne, Australia & Indianapolis, USA | April 10, 2026 Telix Pharmaceuticals has announced that the U.S. Food and Drug...
Clarity Co-PSMA Shows Superior Prostate Cancer Detection
SYDNEY, Australia, March 31, 2026 Clarity Pharmaceuticals has announced the publication of Phase II Co-PSMA clinical trial results in...
TLX101-Px MAA Filed in Europe for Brain Cancer Imaging
MELBOURNE, AUSTRALIA & INDIANAPOLIS, UNITED STATES — February 18, 2026 Telix Pharmaceuticals has submitted a European Marketing Authorization Application...
Advertisements
Telix Reports Phase 3 Success and FDA Progress in Dx
MELBOURNE, Australia; INDIANAPOLIS, United States — December 22, 2025 — Telix Pharmaceuticals Limited has reported a major precision medicine...
IBA Acquires ORA to Strengthen Nuclear Medicine Leadership
Louvain-La-Neuve, Belgium, December 19, 2025 — IBA (Ion Beam Applications S.A.), a global leader in particle accelerator technology and...
NeuroSigma Study Reveals Real-Time Brain Effects of eTNS
Los Angeles, California – November 3, 2025 NeuroSigma, Inc., a Los Angeles-based bioelectronics company, has announced a groundbreaking publication...
Advertisement
